Proveris announces spin-off of inhaler-specific voice guidance technology

Marlborough, MA, February 27, 2018 – Proveris Scientific announced today the spin-off of real-time, inhaler-specific voice guidance technology to Uneva Health, Inc. The technology is the core of a device/digital health platform Uneva Health is developing to reduce the enormous annual costs of inconsistent dosing caused by improper inhaler use while improving patient engagement and compliance. The platform includes a proprietary device that talks patients through inhaler use steps that are typically missed or done incorrectly, and mobile/web applications for viewing usage data.

“The platform will improve the safety and efficacy of marketed inhalers, and help ensure consistent dose delivery to millions of people suffering from asthma and COPD,” said Sue Farina, Uneva Health’s CEO and former Proveris President. “The opportunity to make a meaningful difference to help improve compliance and patient outcomes, while reducing healthcare costs is tremendous. Physicians and patients are anxiously waiting for the platform to be cleared for the market and see it as particularly helpful for pediatric and geriatric patient populations,” continued Farina.

The technology leverages Proveris Scientific’s decades of experience helping pharmaceutical companies bring effective orally inhaled and nasal drug products to market faster. “We’re excited about the technology’s potential and the fact that Proveris played a role in its creation,” said Chip Leveille, Proveris President. “Uneva Health is focused on the critical factors that affect patient use and we believe it will be very successful.”

Having completed a form factor, functioning hardware prototype, Uneva Health is currently raising seed funding for design-controlled development of its platform and is cultivating relationships for co-marketing opportunities with inhaled drug manufacturers.

About Uneva Health, Inc.


Uneva Health is a device/digital health platform company helping to improve the safety and efficacy of inhaled drug products, increase patient engagement and compliance, and reduce the costs of inconsistent dosing caused by improper drug product use and low patient confidence. The Uneva Health voice guidance platform helps patients when they need it most – when using their inhaled drug products. Headquartered in Massachusetts, the company is leveraging technology created from decades of experience related to the development and delivery of orally inhaled and nasal drug products, and hours of feedback from physicians, clinicians, insurers, and patients. For more information, please visit www.unevahealth.com or contact us at info@unevahealth.com.

About Proveris Scientific:

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development the top spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’ systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

Proveris Appoints Chip Leveille as President to Strengthen Operations, Transform for the Future

Marlborough, MA, February 1, 2018 – Proveris Scientific Corporation today announced Chip Leveille has been named President, effective immediately. As President, Leveille will have responsibility for all areas of corporate operations including Sales, Marketing, Business Development, Support, Product Development, Quality, Operations, Finance and Human Resources. He will report directly to Chief Executive Officer Dino Farina.

Proveris Scientific is a leading provider of services and technology to advance the science of nasal and inhaled drug delivery. “We are proud to name Chip Leveille as President of Proveris Scientific as we are entering an exciting phase,” said Dino Farina, Founder and CEO. “With his extensive commercial experience, Chip will drive the company in accelerated product, application and technology development. Key initiatives include improving how spray and aerosol drug delivery products are brought to market globally, and evaluating opportunities for expansion into new industries.”

Leveille brings extensive experience and insight into sales, marketing, product research and development, operations, corporate development, and regulatory affairs, based on his past senior leadership positions which includes a successful executive consulting business, senior executive and commercial leadership positions in biopharmaceutical technology providers including Affymetrix, BioScale, Helicos, and Zymark Corporation.

“I am very excited to lead Proveris in our next stage of growth,” says Leveille, “Proveris has very strong customer relationships, proven technologies and an untapped potential to provide new and innovative products that will help our customers bring the best performing spray and aerosol products to the global market.”

About Proveris Scientific:


Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development the top spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.